Abstracts - faqs.org

Abstracts

Mass communications

Search abstracts:
Abstracts » Mass communications

Weekend Fry-up helps BBC4 find its target

Article Abstract:

ITV2's The Xtra Factor and Jack Osbourne: Adrenaline Junkie performed well with 1.3 million viewers/7.1% share and 555,000/3.4% share during their respective peaks. BBC4's 60-minute profile Stephen Fry: 50 Not Out had 621,000/3.7% share during its peak. A table of the top 10 first-run shows on BBC, ITV, C4, and Five for 2007 is included.

Author: Rogers, Jon
Publisher: EMAP Maclaren Ltd.
Publication Name: Broadcast
Subject: Mass communications
ISSN: 0040-2788
Year: 2007
British Broadcasting Corp., ITV Network Ltd. ITV2, The Xtra Factor (Television program), Jack Osbourne: Adrenaline Junkie (Television program), Stephen Fry: 50 Not Out (Television program)

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Primeval snaps up healthy 7.2 m audience

Article Abstract:

The 'Primeval' television drama which secured an audience share of 7.2 million among other shows of ITV1 is discussed.

Author: Rogers, Jon
Publisher: EMAP Maclaren Ltd.
Publication Name: Broadcast
Subject: Mass communications
ISSN: 0040-2788
Year: 2007
Television audience ratings, ITV Network Ltd. ITV1

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA



Subjects list: United Kingdom, Television broadcasting industry, Television programs, Market share, Company market share
Similar abstracts:
  • Abstracts: Age of Discovery. CNN targets BBC news audience. Discovery turns fiction into fact
  • Abstracts: Ad slump sees C4 freeze budget. TV makes a difference
  • Abstracts: Mixed fortunes at BBC1 as Hunt takes top job. BBC1's Dinner serves up a rare Sunday hit
  • Abstracts: New Crystal formed. New chief takes reins at Quentel. Cadle hunts Soho for Envy talent
  • Abstracts: Take one for the team. Comedy the American way. Leaving "The Office" behind
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.